Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22

Archive Search


254546 items
4:13 PM, Feb 22, 2018  |  BC Extra | Preclinical News

Patient-derived GI cancer organoids predict treatment response

Researchers at The Institute of Cancer Research have developed a living biobank of metastatic gastrointestinal cancer patient-derived organoids (PDOs), and showed PDOs could help predict patient responses to cancer treatment. In a paper published in Science,...
3:53 PM, Feb 22, 2018  |  BC Innovations | Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
3:16 PM, Feb 22, 2018  |  BC Extra | Politics & Policy

NZ government to continue funding for rare diseases

In a meeting held Thursday by the New Zealand Parliament, Associate Minister of Health Julie Anne Genter said that PHARMAC, the government agency which determines public funding for pharmaceuticals, will continue trial-specific funds for rare...
3:12 PM, Feb 22, 2018  |  BC Extra | Politics & Policy

Prime says drug spending down in 2017

Prime Therapeutics LLC (Eagan, Minn.) said overall member spending in 2017 dropped 0.2% for commercial drugs, 0.8% for Medicare Part D drugs and 5.4% for Medicaid drugs compared to 2016. The PBM said autoimmune drugs were...
3:09 PM, Feb 22, 2018  |  BC Extra | Politics & Policy

FDA regulations down

FDA had a significant slowdown in regulatory actions last year and the fewest guidances in four years, said a new report by PricewaterhouseCoopers's Health Research Institute (HRI). According to the report, FDA Commissioner Scott Gottlieb has...
3:07 PM, Feb 22, 2018  |  BC Extra | Company News

Sangamo, Gilead in $3B cell therapy gene editing deal

Sangamo Therapeutics Inc. (NASDAQ:SGMO) gained $3.20 (14%) to $25.40 on Thursday after partnering with the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) to use Sangamo's zinc finger nuclease (ZFN) and adeno-associated virus (AAV)...
3:04 PM, Feb 22, 2018  |  BC Innovations | Targets & Mechanisms

Molecular mentality

A Science study of gene expression signatures in psychiatric disease patients is the field’s largest transcriptomic readout to date, moving it closer toward molecular characterization of mental disorders. By helping map targets and pathways, the...
2:56 PM, Feb 22, 2018  |  BioCentury | Finance

Belgian Insights

Belgium has provided Europe with a host of pioneering biotechs, led by CEOs who have demonstrated resilience and stamina in the pursuit of homegrown innovation. The opening evening session on May 14 at Bio€quity Europe...
2:56 PM, Feb 22, 2018  |  BC Extra | Clinical News

Apellis reports 18-month data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
2:44 PM, Feb 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Mesoblast's MSCs meet in Phase III for acute GvHD

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company said full data from the trial, which are expected next...